Scholarlink

Purpose <p>Brain metastases (BrMs) frequently manifest in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the optimal treatment approach for these individuals remains controversial. This study aimed to evaluate the cost-effectiveness of adding pemetrexed-platinum chemotherapy to first-line gefitinib in EGFR-mutant NSCLC patients with BrMs, considering the perspective of the Chinese healthcare system.</p> Patients and methods <p>Constructing a Markov model, we simulated disease progression over a 10-year horizon in 4-week intervals. The model included three main health states: progression-free survival (PFS), progressive disease (PD), and death, along with a temporary PFS health state. Transition probabilities were estimated based on the data from the GAP BRAIN trial. Costs and utilities were collected from local public database and literature. One-way and probabilistic sensitivity analyses were employed to assess the robustness of the model.</p> Results <p>In the base case analysis, adding pemetrexed-platinum chemotherapy to first-line gefitinib resulted in an incremental effectiveness of 0.59 quality-adjusted life years (QALYs) and an increase in healthcare costs by $12,298.51. Consequently, the incremental cost-effectiveness ratio (ICER) amounted to $24,887.67/QALY, which fell below the prespecified willingness-to-pay (WTP) threshold of $37,654.50 per QALY. Deterministic sensitivity analysis indicated that, apart from the utility value of the PFS health state of the gefitinib plus chemotherapy (GPP) group, other parameters exerted minimal influence on the results. The probabilistic sensitivity analysis demonstrated that, at the predefined WTP threshold, the combination of gefitinib and chemotherapy was a cost-effective treatment strategy.</p> Conclusion <p>Adding pemetrexed-platinum chemotherapy to first-line gefitinib for EGFR-mutant NSCLC patients with BrMs in China represented a cost-effective treatment strategy from the perspective of the Chinese healthcare system.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月27日

查看全文
  • Ziying Zhao,
  • Maolin Chen,
  • Jiuzhou Du,
  • Yanan Zhao,
  • Liling Zhao,
  • Li Fang,
  • Qiao Liu

摘要

Purpose

Brain metastases (BrMs) frequently manifest in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the optimal treatment approach for these individuals remains controversial. This study aimed to evaluate the cost-effectiveness of adding pemetrexed-platinum chemotherapy to first-line gefitinib in EGFR-mutant NSCLC patients with BrMs, considering the perspective of the Chinese healthcare system.

Patients and methods

Constructing a Markov model, we simulated disease progression over a 10-year horizon in 4-week intervals. The model included three main health states: progression-free survival (PFS), progressive disease (PD), and death, along with a temporary PFS health state. Transition probabilities were estimated based on the data from the GAP BRAIN trial. Costs and utilities were collected from local public database and literature. One-way and probabilistic sensitivity analyses were employed to assess the robustness of the model.

Results

In the base case analysis, adding pemetrexed-platinum chemotherapy to first-line gefitinib resulted in an incremental effectiveness of 0.59 quality-adjusted life years (QALYs) and an increase in healthcare costs by $12,298.51. Consequently, the incremental cost-effectiveness ratio (ICER) amounted to $24,887.67/QALY, which fell below the prespecified willingness-to-pay (WTP) threshold of $37,654.50 per QALY. Deterministic sensitivity analysis indicated that, apart from the utility value of the PFS health state of the gefitinib plus chemotherapy (GPP) group, other parameters exerted minimal influence on the results. The probabilistic sensitivity analysis demonstrated that, at the predefined WTP threshold, the combination of gefitinib and chemotherapy was a cost-effective treatment strategy.

Conclusion

Adding pemetrexed-platinum chemotherapy to first-line gefitinib for EGFR-mutant NSCLC patients with BrMs in China represented a cost-effective treatment strategy from the perspective of the Chinese healthcare system.